BAT 7104
Alternative Names: BAT-7104Latest Information Update: 03 Jul 2023
At a glance
- Originator Bio-Thera Solutions
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Solid tumours
- Phase 0 Lymphoma
Most Recent Events
- 03 Jul 2023 Phase-II clinical trials in Solid tumours (Parenteral) (Bio-Thera Solutions pipeline, July 2023)
- 09 May 2022 Adverse events and pharmacodynamics data from a preclinical trial in cancer released by Bio-Thera Solutions
- 01 Feb 2022 Phase-I clinical trials in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Australia (Parenteral) (NCT05200013)